MigraineMind research summary
Onabotulinum Toxin A (BoNTA) in the Treatment of Chronic and High-Frequency Episodic Migraine: A Real-World Study.
Pharmaceuticals (Basel) | 2026
Observational studySummary
OnabotulinumtoxinA (BoNTA) is a treatment for chronic migraine (CM) and high-frequency episodic migraine (HFEM). This study looked at 136 CM patients and 71 HFEM patients. All had tried other oral treatments before using BoNTA. The researchers collected data over 18 years at a single center. They found that 65.4% of CM patients and 71.8% of HFEM patients had a significant reduction in headache days. Both groups experienced fewer headache days and less intense headaches. Additionally, they responded better to other migraine treatments. The average duration of relief for CM patients was about 3.66 months. For HFEM patients, it was about 3.78 months. Overall, BoNTA appears effective for both types of migraine, providing meaningful relief for many patients. This research helps clarify BoNTA's role in treating different migraine forms. Clinical relevance: This study supports the use of BoNTA for chronic and high-frequency episodic migraine, offering patients effective relief from debilitating headache days.
Key Learning Points
- OnabotulinumtoxinA is an effective treatment option for both chronic migraine and high-frequency episodic migraine.
- A significant percentage of patients experienced a reduction in headache days after using OnabotulinumtoxinA.
- Patients reported less intense headaches and improved responses to other migraine treatments after OnabotulinumtoxinA.
- The average duration of relief from headaches was approximately 3.66 months for chronic migraine patients and 3.78 months for high-frequency episodic migraine patients.
- This research highlights the importance of OnabotulinumtoxinA in managing different forms of migraine effectively.
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.